CJC-1295 No-DAC

Technical specifications

Reference specifications describe the material. They do not replace the analytical results for a specific batch.

Chemical name

[D-Ala2, Gln8, Ala15, Leu27]-GHRH(1-29) amide

Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Molecular formula

Not available

Molecular weight

Not available

CAS number

863288-34-0

Form

Lyophilized powder

Appearance

White to off-white solid

Purity specification

Declared in the batch certificate

Identity

Declared in the batch certificate

Solubility

Soluble in sterile water and bacteriostatic water

Storage

−20 °C, protected from light

Stability after reconstitution

Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol

Batch documentation

Review documentation for the product and variant you are purchasing. A reference specification, a research publication and an individual batch certificate are different sources. Ask support which documents are available for your chosen variant and batch. No analytical result should be assumed from a catalog specification.

Laboratory handling

Reconstitution

Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage

Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment

Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Research references

The bibliography brings together work on the analog with DAC and analytical studies that distinguish the two variants. PMID 34665524 includes CJC-1295 without DAC in in vitro research; it does not establish its exposure in humans. Findings for the variant with DAC do not carry over to this preparation.

1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

   Endocrinology · 2005 · PMID 15817669

2. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

   Front Endocrinol (Lausanne) · 2026 · PMID 42395176

3. Advances in the detection of growth hormone releasing hormone synthetic analogs

   Drug Test Anal · 2021 · PMID 34665524

4. Glycine-modified growth hormone secretagogues identified in seized doping material

   Drug Test Anal · 2019 · PMID 30136411

5. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation

   Drug Test Anal · 2010 · PMID 21204297

Read more about this material

• Analytical Half-Life and Response Duration

Frequently asked questions